273 related articles for article (PubMed ID: 15968426)
21. Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas.
Ikeda H
Brain Tumor Pathol; 2006 Apr; 23(1):7-12. PubMed ID: 18095113
[TBL] [Abstract][Full Text] [Related]
22. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription.
Shimon I; Hüttner A; Said J; Spirina OM; Melmed S
J Clin Invest; 1996 Jan; 97(1):187-95. PubMed ID: 8550832
[TBL] [Abstract][Full Text] [Related]
23. [The effects of gastrin-releasing peptide (GRP) and vasoactive intestinal polypeptide (VIP) on the prolactin (PRL) gene transcription of pitutitary PRL releasing tumor of rat].
Di AK; Shan HM; Huang MY; Xu RK
Sheng Li Xue Bao; 1997 Feb; 49(1):79-87. PubMed ID: 9812837
[TBL] [Abstract][Full Text] [Related]
24. Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Bai JW; Wang Z; Gui SB; Zhang YZ
Oncol Rep; 2012 Aug; 28(2):714-20. PubMed ID: 22580984
[TBL] [Abstract][Full Text] [Related]
25. Melatonin supplementation decreases prolactin synthesis and release in rat adenohypophysis: correlation with anterior pituitary redox state and circadian clock mechanisms.
Jiménez-Ortega V; Barquilla PC; Pagano ES; Fernández-Mateos P; Esquifino AI; Cardinali DP
Chronobiol Int; 2012 Oct; 29(8):1021-35. PubMed ID: 22891630
[TBL] [Abstract][Full Text] [Related]
26. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
[TBL] [Abstract][Full Text] [Related]
27. Studies on in vivo gene transfer in pituitary tumors using herpes-derived and adenoviral vectors.
Carri NG; Sosa YE; Brown OA; Albariño C; Romanowski V; Goya RG
Brain Res Bull; 2005 Feb; 65(1):17-22. PubMed ID: 15680541
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
29. Co-regulation of pituitary tumor cell adhesion and prolactin gene expression by glucocorticoid.
Spangler PR; Delidow BC
J Cell Physiol; 1998 Jan; 174(1):115-24. PubMed ID: 9397162
[TBL] [Abstract][Full Text] [Related]
30. Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas.
Cónsole GM; Hereñú CB; Camihort GA; Luna GC; Ferese C; Goya RG
Cells Tissues Organs; 2009; 190(1):20-6. PubMed ID: 18957836
[TBL] [Abstract][Full Text] [Related]
31. Elevated levels of mitochonrial respiratory complexes activities and ATP production in 17-β-estradiol-induced prolactin-secretory tumor cells in male rats are inhibited by melatonin in vivo and in vitro.
Wang BQ; Yang QH; Xu RK; Xu JN
Chin Med J (Engl); 2013; 126(24):4724-30. PubMed ID: 24342319
[TBL] [Abstract][Full Text] [Related]
32. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone-responsive elements of the prolactin gene: evidence for both positive and negative regulation.
Day RN; Maurer RA
Mol Endocrinol; 1989 Jun; 3(6):931-8. PubMed ID: 2739656
[TBL] [Abstract][Full Text] [Related]
34. Relationship of polymorphisms near the rat prolactin, N-ras, and retinoblastoma genes with susceptibility to estrogen-induced pituitary tumors.
Shepel LA; Gorski J
Cancer Res; 1990 Dec; 50(24):7920-5. PubMed ID: 1979252
[TBL] [Abstract][Full Text] [Related]
35. Interactions between rat prolactin gene promoter and enhancer regions in mammosomatotrope and lactotrope cell lines.
Jones GJ; Catanzaro DF
Mol Endocrinol; 1991 Dec; 5(12):1836-44. PubMed ID: 1791833
[TBL] [Abstract][Full Text] [Related]
36. From prolactin cell to prolactinoma.
Velkeniers B
Verh K Acad Geneeskd Belg; 2001; 63(6):561-73; discussion 574-6. PubMed ID: 11813510
[TBL] [Abstract][Full Text] [Related]
37. Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells.
Zhang W; Murao K; Imachi H; Iwama H; Chen K; Fei Z; Zhang X; Ishida T; Tamiya T
Horm Metab Res; 2010 Jul; 42(8):557-61. PubMed ID: 20411477
[TBL] [Abstract][Full Text] [Related]
38. Effect of new SNP within bovine prolactin gene enhancer region on expression in the pituitary gland.
Brym P; Malewski T; Starzyński R; Flisikowski K; Wójcik E; Ruść A; Zwierzchowski L; Kamiński S
Biochem Genet; 2007 Oct; 45(9-10):743-54. PubMed ID: 17929163
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion.
Bolognani F; Albariño C; Romanowski V; Carri NG; Goya RG
Eur J Endocrinol; 2001 Oct; 145(4):497-503. PubMed ID: 11581010
[TBL] [Abstract][Full Text] [Related]
40. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors.
Friedman E; Adams EF; Höög A; Gejman PV; Carson E; Larsson C; De Marco L; Werner S; Fahlbusch R; Nordenskjöld M
J Clin Endocrinol Metab; 1994 Mar; 78(3):568-74. PubMed ID: 7907340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
